Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment
用于治疗急性偏头痛的长效外周限制型κ阿片受体激动剂
基本信息
- 批准号:10487454
- 负责人:
- 金额:$ 19.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-15 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAftercareAlbuminsAmino AcidsAnimal ModelBindingBiological AvailabilityCalcitonin Gene-Related PeptideCanis familiarisChemicalsChronic Kidney FailureDataDevelopmentDoseDrug KineticsDura MaterExhibitsFatty AcidsFemaleFormulationFreedomGenerationsGoalsHalf-LifeHourHumanInflammation MediatorsInpatientsIntravenousInvestigational New Drug ApplicationKidneyLeadMedicalMigraineModalityMolecular WeightMonoclonal AntibodiesMusNociceptionNon-Steroidal Anti-Inflammatory AgentsOpioid agonistOralOutpatientsPainPatientsPeptidesPeripheralPersonsPharmaceutical PreparationsPhasePreventive treatmentPruritusQuality of lifeRenal functionSeriesSerum AlbuminSmall Business Innovation Research GrantSolubilityTabletsTechnologyTransgenic MiceVertebral columnabsorptionacute carebaseclinical candidatedesignfollow-upimprovedinnovationkappa opioid receptorslead optimizationmalemigraine treatmentmouse modelnovelpharmacophorepreventprogramsprototypepublic health relevancereceptorscreeningstandard of caresuccesstriptans
项目摘要
ABSTRACT:
Migraine is a highly prevalent and disabling illness affecting about 47 million people in the US.1 First-line
therapies consist of acute treatments such as non-steroidal anti-inflammatory drugs (NSAIDS), triptans, ditans
or gepants.2 Unfortunately, acute therapies are often poorly effective in many patients. Only about 20-30% of
patients achieve freedom of pain at 2 hours post treatment with any of these drug classes.3-11 Non-responders
to acute therapies with frequent episodic migraine are potential candidates for preventive treatments,2 including
recently approved monoclonal antibodies (mAbs) for calcitonin gene-related peptide (CGRP) and its receptor
(GGRPR).12-16 CGRP and CGRPR mAbs reduce the number of migraine days per month by 50% in 40-60% of
patients,12-16 thus achieving only partial relief in responders and leaving a large group of non-responders without
improvement. Overall, there are still large unmet medical needs in migraine, specifically for novel, and broadly
effective acute treatments.
We recently demonstrated that the peripheral kappa-opioid receptor (KOR) is a novel target for acute migraine
treatment. We showed that the peripherally restricted KOR agonist difelikefalin reverses established migraine-
like pain in mice resulting from direct activation of nociceptive afferents with a cocktail of inflammatory mediators
(IM) applied to the dura mater. Our data suggest that peripherally restricted KOR agonists have the potential to
be broadly effective and to achieve high efficacy for acute migraine treatment.
The goal of this program is to develop long acting, peripherally restricted and hence non addictive, kappa-opioid
receptor (KOR) agonists as novel, safe, and broadly effective acute migraine treatments. The proposed SBIR
Phase I program will select a clinical candidate for development able to treat migraine headache and suitable for
once-daily dosing, both as an intravenous (IV) formulation for use in inpatient settings or as an oral tablet for use
in outpatient settings.
Impact and
摘要:
偏头痛是一种高度流行和致残的疾病,影响着美国第一线约4700万人。
治疗包括急性治疗,如非类固醇抗炎药(NSAIDs)、Triptans、Ditans
不幸的是,急性治疗在许多患者中往往效果不佳。只有大约20%-30%的
患者在使用这些药物类别的任何一种药物治疗后2小时内实现疼痛自由。3-11无反应者
有频繁发作偏头痛的急性疗法是预防性治疗的潜在候选者,2包括
新近研制的抗降钙素基因相关肽及其受体的单抗
(GGRPR).12-16 CGRP和CGRPR单抗每月可将偏头痛天数减少50%-40%-60%
患者,12-16人,因此仅实现了应答者的部分缓解,并使一大批无应答者
进步。总体而言,偏头痛仍有大量未得到满足的医疗需求,特别是新奇和广泛的
有效的急诊治疗。
我们最近证实外周kappa-阿片受体(KOR)是治疗急性偏头痛的新靶点。
治疗。我们发现,外周受限的KOR激动剂达菲凯法林可以逆转已建立的偏头痛--
直接激活伤害性传入与炎性介质的混合物所致的小鼠疼痛
(IM)应用于硬脑膜。我们的数据表明,外周受限的KOR激动剂有可能
对急性偏头痛的治疗具有广泛的疗效和较高的疗效。
该计划的目标是开发长效、外周受限的、因此不会上瘾的kappa-阿片类药物。
受体(KOR)激动剂作为新的、安全和广泛有效的急性偏头痛治疗药物。建议的SBIR
第一阶段计划将选择一种能够治疗偏头痛并适用于
每日一次,作为静脉(IV)制剂在住院环境中使用或作为口服片剂使用
在门诊环境中。
影响和
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pierre Riviere其他文献
Pierre Riviere的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pierre Riviere', 18)}}的其他基金
Peptide-antibody conjugate kappa-opioid receptor (PAC-KOR) agonists for treatment of chronic itch
用于治疗慢性瘙痒的肽抗体缀合物 kappa-阿片受体 (PAC-KOR) 激动剂
- 批准号:
10481985 - 财政年份:2022
- 资助金额:
$ 19.94万 - 项目类别:
Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes
用于治疗女性为主的疼痛综合征的催乳素单克隆抗体 (PRL-mAb)
- 批准号:
10438871 - 财政年份:2021
- 资助金额:
$ 19.94万 - 项目类别:
Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes
用于治疗女性为主的疼痛综合征的催乳素单克隆抗体 (PRL-mAb)
- 批准号:
10255683 - 财政年份:2021
- 资助金额:
$ 19.94万 - 项目类别:
Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment
用于治疗急性偏头痛的长效外周限制型κ阿片受体激动剂
- 批准号:
10324497 - 财政年份:2021
- 资助金额:
$ 19.94万 - 项目类别:
Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain
外周限制性长效生长抑素受体 4 (LA-SSTR4) 激动剂治疗疼痛
- 批准号:
10022491 - 财政年份:2019
- 资助金额:
$ 19.94万 - 项目类别:
Bi-Functional Peptides to Block Vasodilation and Vascular Leakage in Sepsis
双功能肽可阻断脓毒症中的血管舒张和血管渗漏
- 批准号:
9408431 - 财政年份:2017
- 资助金额:
$ 19.94万 - 项目类别:
Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain
外周限制性长效 κ 阿片受体 (LA-KOR) 激动剂用于治疗疼痛
- 批准号:
9753194 - 财政年份:2016
- 资助金额:
$ 19.94万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Studentship